Progesterone Receptor-B Induction of BIRC3 Protects Endometrial Cancer Cells from AP1-59-Mediated Apoptosis

Hormones and Cancer

Volumn 2, Issue 3, 2011, Pages 170-181

  Neubauer, Nikki L ^a   Ward, Erin C ^b   Patel, Parin ^b   Lu, Zhenxiao ^b   Lee, Irene ^b   Blok, Leen J ^c   Hanifi Moghaddam, Payman ^c   Schink, Julian ^a   Kim, J Julie ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

BIRC3; Endometrial cancer; Progesterone receptor

Indexed keywords

API 59; PROGESTERONE RECEPTOR B; PROMEGESTONE; PROTEIN BIRC3; PROTEIN DERIVATIVE; PROTEIN KINASE B INHIBITOR; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENDOMETRIUM CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; ELLIPTICINES; ENDOMETRIAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, PROGESTERONE; RNA, SMALL INTERFERING;

EID: 79955648505     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-011-0065-7     Document Type: Article

References (53)

1. Clarke CL, Sutherland RL (1990) Progestin regulation of cellular proliferation. Endocr Rev 11(2): 266-301.
2. Creasman WT (1997) Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin Oncol 24(1 Suppl 1): S1-140-S141-150.
3. Munstedt K, Grant P, Woenckhaus J, Roth G, Tinneberg HR (2004) Cancer of the endometrium: current aspects of diagnostics and treatment. World J Surg Oncol 2: 24. doi: 10. 1186/1477-7819-2-24.
4. Chiva L, Lapuente F, Gonzalez-Cortijo L, Carballo N, Garcia JF, Rojo A, Gonzalez-Martin A (2008) Sparing fertility in young patients with endometrial cancer. Gynecol Oncol 111(2 Suppl): S101-S104. doi: 10. 1016/j. ygyno. 2008. 07. 056.
5. Kim JJ, Chapman-Davis E (2010) Role of progesterone in endometrial cancer. Semin Reprod Med 28(1): 81-90. doi: 10. 1055/s-0029-1242998.
6. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9(5): 1603-1614.
7. Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP (2000) The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 20(9): 3102-3115.
8. Smid-Koopman E, Blok LJ, Kuhne LC, Burger CW, Helmerhorst TJ, Brinkmann AO, Huikeshoven FJ (2003) Distinct functional differences of human progesterone receptors A and B on gene expression and growth regulation in two endometrial carcinoma cell lines. J Soc Gynecol Investig 10(1): 49-57.
9. Tung L, Abdel-Hafiz H, Shen T, Harvell DM, Nitao LK, Richer JK, Sartorius CA, Takimoto GS, Horwitz KB (2006) Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. Mol Endocrinol 20(11): 2656-2670. doi: 10. 1210/me. 2006-0105.
10. Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB (1993) Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol 7(10): 1256-1265.
11. Fujimoto J, Ichigo S, Hori M, Nishigaki M, Tamaya T (1995) Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors. Tumour Biol 16(4): 254-260.
12. Arnett-Mansfield RL, deFazio A, Wain GV, Jaworski RC, Byth K, Mote PA, Clarke CL (2001) Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 61(11): 4576-4582.
13. Kumar NS, Richer J, Owen G, Litman E, Horwitz KB, Leslie KK (1998) Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. Cancer Res 58(9): 1860-1865.
14. Jongen V, Briet J, de Jong R, ten Hoor K, Boezen M, van der Zee A, Nijman H, Hollema H (2009) Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 112(3): 537-542. doi: 10. 1016/j. ygyno. 2008. 10. 032.
15. Dai D, Wolf DM, Litman ES, White MJ, Leslie KK (2002) Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res 62(3): 881-886.
16. Ueda M, Fujii H, Yoshizawa K, Abe F, Ueki M (1996) Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG-M cells in vitro. Jpn J Cancer Res 87(5): 524-533.
17. Hanekamp EE, Kuhne LM, Grootegoed JA, Burger CW, Blok LJ (2004) Progesterone receptor A and B expression and progestagen treatment in growth and spread of endometrial cancer cells in nude mice. Endocr Relat Cancer 11(4): 831-841. doi: 10. 1677/erc. 1. 00844.
18. Ward EC, Hoekstra AV, Blok LJ, Hanifi-Moghaddam P, Lurain JR, Singh DK, Buttin BM, Schink JC, Kim JJ (2008) The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma. Endocrinology 149(4): 1942-1950. doi: 10. 1210/en. 2007-0756.
19. Hecht JL, Mutter GL (2006) Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24(29): 4783-4791. doi: 10. 1200/JCO. 2006. 06. 7173.
20. Risinger JI, Hayes AK, Berchuck A, Barrett JC (1997) PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57(21): 4736-4738.
21. Gagnon V, van Themsche C, Turner S, Leblanc V, Asselin E (2008) Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 13(2): 259-271. doi: 10. 1007/s10495-007-0165-6.
22. Jin X, Gossett DR, Wang S, Yang D, Cao Y, Chen J, Guo R, Reynolds RK, Lin J (2004) Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells. Br J Cancer 91(10): 1808-1812. doi: 10. 1038/sj. bjc. 6602214.
23. Kanamori Y, Kigawa J, Itamochi H, Shimada M, Takahashi M, Kamazawa S, Sato S, Akeshima R, Terakawa N (2001) Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 7(4): 892-895.
24. Gagnon V, St-Germain ME, Parent S, Asselin E (2003) Akt activity in endometrial cancer cells: regulation of cell survival through cIAP-1. Int J Oncol 23(3): 803-810.
25. Nishida M, Kasahara K, Oki A, Satoh T, Arai Y, Kubo T (1996) Establishment of eighteen clones of Ishikawa cells. Hum Cell 9(2): 109-116.
26. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4): 402-408. doi: 10. 1006/meth. 2001. 1262.
27. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, Harran P, Wang X (2007) Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12(5): 445-456. doi: 10. 1016/j. ccr. 2007. 08. 029.
28. Hoekstra AV, Ward EC, Hardt JL, Lurain JR, Singh DK, Buttin BM, Schink JC, Kim JJ (2008) Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1. Gynecol Oncol 108(3): 609-618. doi: 10. 1016/j. ygyno. 2007. 11. 007.
29. Tang HJ, Jin X, Wang S, Yang D, Cao Y, Chen J, Gossett DR, Lin J (2006) A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. Gynecol Oncol 100(2): 308-317. doi: 10. 1016/j. ygyno. 2005. 08. 044.
30. Harding MM, Grummitt AR (2003) 9-Hydroxyellipticine and derivatives as chemotherapy agents. Mini Rev Med Chem 3(2): 67-76.
31. Di Nezza LA, Jobling T, Salamonsen LA (2003) Progestin suppresses matrix metalloproteinase production in endometrial cancer. Gynecol Oncol 89(2): 325-333.
32. Saito T, Mizumoto H, Tanaka R, Satohisa S, Adachi K, Horie M, Kudo R (2004) Overexpressed progesterone receptor form B inhibit invasive activity suppressing matrix metalloproteinases in endometrial carcinoma cells. Cancer Lett 209(2): 237-243. doi: 10. 1016/j. canlet. 2003. 12. 017.
33. Moe BG, Vereide AB, Orbo A, Sager G (2009) High concentrations of progesterone and mifepristone mutually reinforce cell cycle retardation and induction of apoptosis. Anticancer Res 29(4): 1053-1058.
34. Cervantes M, Gonzalez-Vidal MD, Ruelas R, Escobar A, Morali G (2002) Neuroprotective effects of progesterone on damage elicited by acute global cerebral ischemia in neurons of the caudate nucleus. Arch Med Res 33(1): 6-14.
35. Gonzalez-Vidal MD, Cervera-Gaviria M, Ruelas R, Escobar A, Morali G, Cervantes M (1998) Progesterone: protective effects on the cat hippocampal neuronal damage due to acute global cerebral ischemia. Arch Med Res 29(2): 117-124.
36. Morrissy S, Xu B, Aguilar D, Zhang J, Chen QM (2010) Inhibition of apoptosis by progesterone in cardiomyocytes. Aging Cell 9(5): 799-809. doi: 10. 1111/j. 1474-9726. 2010. 00619. x.
37. Gonzalez SL, Labombarda F, Deniselle MC, Mougel A, Guennoun R, Schumacher M, De Nicola AF (2005) Progesterone neuroprotection in spinal cord trauma involves up-regulation of brain-derived neurotrophic factor in motoneurons. J Steroid Biochem Mol Biol 94(1-3): 143-149. doi: 10. 1016/j. jsbmb. 2005. 01. 016.
38. Labombarda F, Gonzalez Deniselle MC, De Nicola AF, Gonzalez SL (2010) Progesterone and the spinal cord: good friends in bad times. Neuroimmunomodulation 17(3): 146-149. doi: 10. 1159/000258709.
39. Vares G, Ory K, Lectard B, Levalois C, Altmeyer-Morel S, Chevillard S, Lebeau J (2004) Progesterone prevents radiation-induced apoptosis in breast cancer cells. Oncogene 23(26): 4603-4613. doi: 10. 1038/sj. onc. 1207601.
40. Chen H, Wu Z, Li J, Chen R, Yu Y, Xu L, Shuai J, Tu YT (2009) Effect of progesterone on gonococci-induced apoptosis and respiratory burst of human polymorphonuclear leukocytes in vitro. Int J Dermatol 48(9): 1011-1016. doi: 10. 1111/j. 1365-4632. 2009. 04177. x.
41. Quiles I, Millan-Arino L, Subtil-Rodriguez A, Minana B, Spinedi N, Ballare C, Beato M, Jordan A (2009) Mutational analysis of progesterone receptor functional domains in stable cell lines delineates sets of genes regulated by different mechanisms. Mol Endocrinol 23(6): 809-826. doi: 10. 1210/me. 2008-0454.
42. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277(7): 5209-5218. doi: 10. 1074/jbc. M110090200.
43. Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, Lin CY, Stanculescu A (2009) Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res 69(23): 8918-8925. doi: 10. 1158/0008-5472. CAN-09-2608.
44. Stanculescu A, Bembinster LA, Borgen K, Bergamaschi A, Wiley E, Frasor J (2010) Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner. Horm Canc 1: 127-135. doi: 10. 1007/s12672-010-0018-6.
45. Runnebaum IB, Bruning A (2005) Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2. Clin Cancer Res 11(17): 6325-6332. doi: 10. 1158/1078-0432. CCR-05-0182.
46. Karasawa H, Miura K, Fujibuchi W, Ishida K, Kaneko N, Kinouchi M, Okabe M et al (2009) Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci 100(5): 903-913. doi: 10. 1111/j. 1349-7006. 2009. 01112. x.
47. Petersen SL, Peyton M, Minna JD, Wang X (2010) Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Proc Natl Acad Sci USA 107(26): 11936-11941. doi: 10. 1073/pnas. 1005667107.
48. Chen DJ, Huerta S (2009) Smac mimetics as new cancer therapeutics. Anticancer Drugs 20(8): 646-658. doi: 10. 1097/CAD. 0b013e32832ced78.
49. Dai Y, Lawrence TS, Xu L (2009) Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am J Transl Res 1(1): 1-15.
50. Dineen SP, Roland CL, Greer R, Carbon JG, Toombs JE, Gupta P, Bardeesy N et al (2010) Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 70(7): 2852-2861. doi: 10. 1158/0008-5472. CAN-09-3892.
51. Lecis D, Drago C, Manzoni L, Seneci P, Scolastico C, Mastrangelo E, Bolognesi M et al (2010) Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. Br J Cancer 102(12): 1707-1716. doi: 10. 1038/sj. bjc. 6605687.
52. Orzaez M, Gortat A, Mondragon L, Perez-Paya E (2009) Peptides and peptide mimics as modulators of apoptotic pathways. ChemMedChem 4(2): 146-160. doi: 10. 1002/cmdc. 200800246.
53. Probst BL, Liu L, Ramesh V, Li L, Sun H, Minna JD, Wang L (2010) Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-alpha-dependent manner. Cell Death Differ 17(10): 1645-1654. doi: 10. 1038/cdd. 2010. 44.